Codexis (CDXS) Stock Rating Upgraded by BidaskClub
Codexis (NASDAQ:CDXS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Friday.
A number of other equities research analysts have also weighed in on CDXS. Jefferies Group reaffirmed a “buy” rating and set a $9.00 price target (up from $8.00) on shares of Codexis in a report on Monday, October 2nd. HC Wainwright reiterated a “buy” rating and issued a $8.50 price objective on shares of Codexis in a research report on Tuesday, November 21st. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, ValuEngine upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Codexis presently has a consensus rating of “Buy” and a consensus target price of $7.50.
Codexis (NASDAQ CDXS) traded up $0.15 during trading hours on Friday, reaching $7.70. 300,009 shares of the company’s stock were exchanged, compared to its average volume of 224,575. Codexis has a 12 month low of $3.60 and a 12 month high of $7.95.
TRADEMARK VIOLATION WARNING: “Codexis (CDXS) Stock Rating Upgraded by BidaskClub” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/codexis-cdxs-stock-rating-upgraded-by-bidaskclub/1769998.html.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.